Scientific Advisory Board

Gordon Keller, Ph.D

Dr. Gordon Keller earned his PhD in Immunology at the University of Alberta in 1979 and completed a Post Doctoral Fellowship at the Ontario Cancer Institute in Toronto in 1983.  Following post doctoral studies, he became a Member of the Basel Institute for Immunology in Switzerland where he worked for five years, then moved to Vienna Austria where he accepted a post of Visiting Scientist at the Research Institute of Molecular Pathology.  In 1990, Keller moved to the United States, working initially at the National Jewish Centre for Immunology and Respiratory Medicine in Denver Colorado and from 1999-2006 as a Professor in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine in New York. In 2005, he was appointed as the Director of the Black Family Stem Cell Institute within the Mt. Sinai School of Medicine. As of January 2007, Keller returned to Canada to accept the position of Director of the McEwen Centre for Regenerative Medicine at the University Health Network in Toronto.  Dr. Keller is best known for his research in lineage specific differentiation of mouse and human embryonic stem cells.

Paul Fairchild, DPhil

Paul Fairchild began his research career in Oxford, where he studied for a doctorate in the Nuffield Department of Surgical Sciences, focussing on the dual role of dendritic cells in allograft rejection and immunological self-tolerance.  After spending five years as a Post-doctoral Fellow investigating the etiology of autoimmune disease in the Department of Pathology, University of Cambridge, he returned to Oxford, where he is currently Associate Professor within the Sir William Dunn School of Pathology and a Fellow of Trinity College.  In 2008, Paul Fairchild founded the Oxford Stem Cell Institute (OSCI), for which he served as Co-Director until the end of 2015.  His current research continues to draw on his background in transplantation immunology, in order to investigate the nature of the immune response to tissues differentiated from pluripotent stem cells and to develop approaches to the induction and maintenance of immunological tolerance.  Furthermore, he has developed a program of research aimed at exploiting the properties of pluripotent stem cells to address unmet medical needs with an immunological basis and has filed several patents focussing on the derivation of dendritic cell subsets from human iPSC for use in immunotherapy.


Rob Coffin, Ph.D

Robert Coffin is CEO and co-founder of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his prior research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC) that was recently approved by the FDA and is the first gene therapy product ever approved in the USA. Rob oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer under SPA before sale of BioVex to Amgen in 2011 where he became VP Global Development until 2013. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991. Subsequent to Amgen, Rob has provided general biotech advisory services in gene therapy, oncolytic viruses, oncology drug development, cell therapy, immunotherapy and vaccines including in particular to Uniqure and Universal Cells Inc.

Melissa Carpenter, Ph.D

For the last 20 years, Melissa Carpenter has worked on the development of cell therapies using human adult and embryonic stem cells, in academia and industry, in the United States and Canada. She has been involved with human embryonic stem cell (hESC) research since the field was established. Her work involves discovery research and the translation of this research into therapeutics, including developing strategies for preclinical development and navigating the regulatory issues surrounding stem cell therapies. She has held leadership positions at 3 of the major stem cell companies: CytoTherapeutics, Inc (StemCells, Inc), Geron, Corp., and Novocell, Inc (Viacyte, Inc). Currently Melissa is President of Carpenter Group Consulting and works with early stage companies, academic groups and investors to translate discovery based research into stem cell therapies. She is credited with numerous publications and patents in the stem cell field. Melissa received her B.S. from University of Oregon and her PhD from University of California, Irvine.